Fresenius Kabi Awaits EMA Inspection For Pegfilgrastim Biosimilar
Facing Greater Challenge For FDA Approval
Having recently announced plans to launch a further four biosimilar products in the next four years, Fresenius Kabi has disclosed the latest on its bid to introduce pegfilgrastim, which has been hamstrung in the US by delayed inspections.
